image
Healthcare - Medical - Devices - NASDAQ - US
$ 7.09
0.71 %
$ 188 M
Market Cap
-4.66
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one INGN stock under the worst case scenario is HIDDEN Compared to the current market price of 7.09 USD, Inogen, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one INGN stock under the base case scenario is HIDDEN Compared to the current market price of 7.09 USD, Inogen, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one INGN stock under the best case scenario is HIDDEN Compared to the current market price of 7.09 USD, Inogen, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INGN

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
336 M REVENUE
6.35%
-42.5 M OPERATING INCOME
61.13%
-35.9 M NET INCOME
64.97%
5.91 M OPERATING CASH FLOW
282.87%
-14 M INVESTING CASH FLOW
76.44%
265 K FINANCING CASH FLOW
-72.40%
80.1 M REVENUE
-9.85%
-11.4 M OPERATING INCOME
-46.12%
-9.76 M NET INCOME
-63.63%
-3.02 M OPERATING CASH FLOW
-43.16%
11.5 M INVESTING CASH FLOW
3683.61%
-260 K FINANCING CASH FLOW
-58.96%
Balance Sheet Inogen, Inc.
image
Current Assets 185 M
Cash & Short-Term Investments 114 M
Receivables 29.6 M
Other Current Assets 42.1 M
Non-Current Assets 111 M
Long-Term Investments 0
PP&E 62.7 M
Other Non-Current Assets 48 M
38.42 %9.98 %14.21 %21.17 %16.22 %Total Assets$296.2m
Current Liabilities 76.7 M
Accounts Payable 16.6 M
Short-Term Debt 2.81 M
Other Current Liabilities 57.3 M
Non-Current Liabilities 45.6 M
Long-Term Debt 16.6 M
Other Non-Current Liabilities 29 M
13.58 %46.81 %13.57 %23.74 %Total Liabilities$122.3m
EFFICIENCY
Earnings Waterfall Inogen, Inc.
image
Revenue 336 M
Cost Of Revenue 181 M
Gross Profit 155 M
Operating Expenses 197 M
Operating Income -42.5 M
Other Expenses -6.63 M
Net Income -35.9 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)336m(181m)155m(197m)(43m)7m(36m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
46.09% GROSS MARGIN
46.09%
-12.66% OPERATING MARGIN
-12.66%
-10.69% NET MARGIN
-10.69%
-20.64% ROE
-20.64%
-12.12% ROA
-12.12%
-18.82% ROIC
-18.82%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Inogen, Inc.
image
60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -35.9 M
Depreciation & Amortization 21 M
Capital Expenditures 0
Stock-Based Compensation 7.4 M
Change in Working Capital 0
Others 14.6 M
Free Cash Flow 5.91 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Inogen, Inc.
image
INGN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Inogen, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
85.6 K USD 1
Bought
125 K USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Inogen To Present at 24th Annual Needham Virtual Healthcare Conference GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen To Present at 24th Annual Needham Virtual Healthcare Conference. businesswire.com - 1 month ago
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
Here's Why You Should Retain Inogen Stock in Your Portfolio Now Inogen, Inc.  INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 performance and a strong product portfolio, seems justified. zacks.com - 1 month ago
A Volatile Share Price Masks Some Of The Progress At Inogen Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage. seekingalpha.com - 1 month ago
What's Going On With MedTech Focused Inogen Stock On Wednesday? Medical Technology company Inogen Inc INGN reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the consensus loss of 61 cents. benzinga.com - 1 month ago
INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales. zacks.com - 1 month ago
Inogen, Inc. (INGN) Q4 2024 Earnings Call Transcript Inogen, Inc. (NASDAQ:INGN ) Q4 2024 Earnings Conference Call February 25, 2025 5:00 PM ET Company Participants Ryan Peterson – Investor Relations Kevin Smith – President and Chief Executive Officer Mike Bourque – Chief Financial Officer Conference Call Participants Operator Welcome to Inogen's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates Inogen (INGN) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $1.14 per share a year ago. zacks.com - 1 month ago
Here's Why You Should Add Inogen Stock to Your Portfolio Now Expanding product portfolio and high prospects for POC raise optimism for INGN stock. zacks.com - 2 months ago
Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West. businesswire.com - 2 months ago
Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market. zacks.com - 2 months ago
Arab Health 2025|Yuwell Medical Announces Strategic Investment and Partnership with Inogen in Respiratory Health DUBAI, UAE, Jan. 26, 2025 /PRNewswire/ -- On the eve of the Arab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai , and announced a strategic investment and partnership with Inogen, a leading U.S. company in respiratory health, highlighting our joint commitment to advancing medical device solutions and deeper collaboration. Speaking at the Yuwell Medical 2025 Global Core Partner Conference, Alex WU, Chairman of Yuwell Medical, stated that as a leading enterprise in China's home medical device industry, Yuwell will rely on internal growth and external mergers and acquisitions to promote internationalisation. prnewswire.com - 2 months ago
8. Profile Summary

Inogen, Inc. INGN

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 188 M
Dividend Yield 0.00%
Description Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Contact 301 Coromar Drive, Goleta, CA, 93117 https://www.inogen.com
IPO Date Feb. 14, 2014
Employees 766
Officers Dr. Krishna Jhaveri Chief Medical Officer Mr. Adrien Mithalal Senior Vice President of Research & Development Mr. Philip Corrin Senior Vice President of Operations & Supply Chain Mr. Grgoire Ramade Executive Vice President & Chief Commercial Officer Mr. Kevin R. M. Smith President, Chief Executive Officer & Director Mr. Kevin P. Smith General Counsel, Secretary & Executive Vice President of Business Development Ms. Jennifer Yi Boyer Executive Vice President & Chief Human Resources Officer Mr. Paul Andreassi Senior Vice President of Quality & Regulatory Affairs